The Russian State Research Center for Virology and Biotechnology Vector has started to develop a new vaccine against the coronavirus (COVID-19) in the form of nasal drops, an official said.
Vector chief executive Rinat Maksyutov said in an interview with Sputnik that the vaccine would help provide immunity just at the “gateway” to infection,
“Yes, we have started to develop a vaccine in the form of drops, an intranasal vaccine.
“The composition of the main active component of the vaccine will remain unchanged (the same as that of the EpiVacCorona vaccine),” Maksyutov said.
The vaccine will help build immunity in the nasal mucous membranes, which can be described as the “gateway” to infection, Maksyutov said. (Sputnik / NAN)
Short Link: https://wp.me/pcj2iU-3yGK
- The FG reconstitutes the boards of directors of NABTEB, NSSEC
- SEC accuses traders of frustrating electronic dividend registration
- Correctional center controller recommends amnesty for some inmates
- Society defines May 5 as National Bible Day
- SEC instructs CMOs to update investor information
- Coronavirus – Zambia: COVID-19 update (April 14, 2021)
- FG distributes inputs to 7,500 women farmers
- Intelligence gathering is key to resolving insurgency -GOC
- Coronavirus – Namibia: COVID-19 update (April 14, 2021)